Search research articles
Contact Us
Filters
Showing results (261-270 of 442) with videos related to
Page
of 45
Sort By:
Oncotarget
|
March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
Xiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2021
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S Hong, Kathleen N Moore, Johanna C Bendell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 3, 2003
West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review
David S Hong, Kalen L Jacobson, Issam I Raad, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Cancer
|
July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials
Goldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Journal of Hematology
|
July 15, 2022
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience
Blessie Elizabeth Nelson, Chinenye Lynette Ejezie, Bettzy A Stephen, et al.
International Journal of Cancer
|
November 30, 2019
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies
Shumei Kato, Ryosuke Okamura, Jason K Sicklick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group
Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Page
of 45
Search research articles
Search
Showing results (261-270 of 442) with videos related to
Sort By:
Page
of 45
Oncotarget
|
March 3, 2016
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
Xiaochun Liu, Susan Kambrick, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2021
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S Hong, Kathleen N Moore, Johanna C Bendell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 3, 2003
West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review
David S Hong, Kalen L Jacobson, Issam I Raad, et al.
Molecular Cancer Therapeutics
|
January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
Filip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
Filip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Cancer
|
July 15, 2016
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials
Goldy C George, Eucharia C Iwuanyanwu, Karen O Anderson, et al.
Journal of Hematology
|
July 15, 2022
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience
Blessie Elizabeth Nelson, Chinenye Lynette Ejezie, Bettzy A Stephen, et al.
International Journal of Cancer
|
November 30, 2019
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies
Shumei Kato, Ryosuke Okamura, Jason K Sicklick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group
Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2019
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]
Hossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Page
of 45